Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05297890
What this trial is testing

Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Who this might be right for
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals 70
Large-scale testing (Phase 3)Not Yet RecruitingNCT07816380
What this trial is testing

A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Guangzhou JOYO Pharma Co., Ltd 216
Large-scale testing (Phase 3)Active Not RecruitingNCT06140836
What this trial is testing

Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb 190
Not applicableNo Longer AvailableNCT06841874
What this trial is testing

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

Who this might be right for
Lung NeoplasmsRespiratory Tract NeoplasmsThoracic Neoplasms+8 more
Nuvation Bio Inc.
Large-scale testing (Phase 3)Not Yet RecruitingNCT07154368
What this trial is testing

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Who this might be right for
Non Small Cell Lung Cancer
Guangzhou JOYO Pharma Co., Ltd 207
Testing effectiveness (Phase 2)Looking for participantsNCT04996121
What this trial is testing

XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 360
Large-scale testing (Phase 3)Looking for participantsNCT06564324
What this trial is testing

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Who this might be right for
Non Small Cell Lung Cancer
Nuvation Bio Inc. 194
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Not applicableNot Yet RecruitingNCT07599007
What this trial is testing

Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04919811
What this trial is testing

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Nuvation Bio Inc. 217